Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nivolumab biosimilar - Mabpharm

Next Previous
Drug Profile

Nivolumab biosimilar - Mabpharm

Alternative Names: CMAB 819

Latest Information Update: 19 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sinomab
  • Developer Mabpharm
  • Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Liver cancer; Non-small cell lung cancer; Squamous cell cancer

Most Recent Events

  • 19 Apr 2024 Phase I development for Liver cancer, Non-small cell lung cancer (Metastatic disease) and Squamous cell cancer (Locally recurrent, Metastatic disease, Second-line therapy or greater) is ongoing in China (Taizhou Mabtech Pharmaceutical pipeline, April 2024)
  • 16 Oct 2023 Taizhou Mabtech Pharmaceutical terminates a phase I trial in Squamous cell cancer (Metastatic disease, Locally recurrent, Second-line therapy or greater) in China (IV) due to early positive results due to difficulty in recruiting subjects (NCT04659369)
  • 24 Sep 2020 Phase-I clinical trials in Squamous cell cancer (Metastatic disease, Locally recurrent, Second-line therapy or greater) in China (IV) in September 2020 (NCT04659369)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top